Evolent Health, Inc. announced on August 18, 2025, its intention to offer $140.0 million in aggregate principal amount of convertible senior notes due 2031. Additionally, the company plans to grant initial purchasers an option to buy up to an additional $20.0 million in notes. The notes are aimed at qualified institutional buyers under Rule 144A of the Securities Act of 1933. Evolent intends to use up to $100.0 million of the net proceeds to repurchase a portion of its 1.50% convertible senior notes due 2025, and approximately $40.0 million to repurchase shares of its Class A common stock. The notes and any Class A common stock issuable upon conversion are not registered under the Securities Act or any state securities laws.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。